Research progress on role and mechanism of Salviae Miltiorrhizae Radix et Rhizoma in preventing and treating doxorubicin-induced cardiotoxicity
DUAN Huxinyue1, CHEN Yan1, ZHU Yongxia1, PENG Rui1, LIU Zhixi1, LI Ruolan1, XIAO Hongtao1
Affiliations
1 Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610041, China
doi: 10.7501j.issn.0253-2670.2026.19.028
文章导航
摘要
收起
多柔比星是临床常用的蒽环类抗肿瘤药物，但其剂量相关性和累积性心脏毒性严重限制了长期应用。丹参Salviae Miltiorrhizae Radix et Rhizoma及其制剂在实验与临床研究中展现出抗多柔比星心脏毒性的潜力。系统回顾了丹参提取物、活性成分（丹参酮I、丹参酮IIA、丹酚酸B等）、复方及中成药通过抑制氧化应激、凋亡、焦亡、炎症等多途径保护心肌的机制。与既往综述主要聚焦单一活性成分或心血管保护作用不同，比较了丹参来源的不同成分在多柔比星心脏毒性中的作用特点及机制差异，并基于当前研究现状，分析临床转化亟待突破的关键瓶颈，为临床应用和药物开发提供参考。
关键词
丹参
/
多柔比星
/
心脏毒性
/
氧化应激
/
炎症
Abstract
收起
Doxorubicin (DOX) is a widely used anthracycline anticancer agent; however, its dose-dependent and cumulative cardiotoxicity severely limits its long-term clinical use. Danshen (Salviae Miltiorrhizae Radix et Rhizoma) and Salviae Miltiorrhizae Radix et Rhizoma-based preparations have shown potential for the prevention and treatment of DOX-induced cardiotoxicity in both experimental and clinical studies. This review systematically summarizes the cardioprotective mechanisms of Salviae Miltiorrhizae Radix et Rhizoma extracts, active constituents (including tanshinone I, tanshinone IIA, and salvianolic acid B), Salviae Miltiorrhizae Radix et Rhizoma-containing herbal formulas, and Chinese patent medicines, with particular emphasis on their inhibitory effects on oxidative stress, apoptosis, pyroptosis, inflammation, and other pathological processes. Unlike previous reviews that have focused primarily on individual active constituents or the general cardiovascular protective effects of Salviae Miltiorrhizae Radix et Rhizoma, this review compares the pharmacological characteristics and mechanistic differences among different Salviae Miltiorrhizae Radix et Rhizoma-derived components in DOX-induced cardiotoxicity. Based on the current evidence, key barriers to clinical translation are further discussed to provide a reference for the clinical application and drug development of Salviae Miltiorrhizae Radix et Rhizoma-derived therapies.
DUAN Huxinyue, CHEN Yan, ZHU Yongxia, PENG Rui, LIU Zhixi, LI Ruolan, XIAO Hongtao.
Research progress on role and mechanism of Salviae Miltiorrhizae Radix et Rhizoma in preventing and treating doxorubicin-induced cardiotoxicity[J].
Chinese Traditional and Herbal Drugs,
2026
, 57
(19)
: 7850
-7860
.
DOI: 10.7501j.issn.0253-2670.2026.19.028
Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249. Wenningmann N, Knapp M, Ande A, et al. Insights into doxorubicin-induced cardiotoxicity: Molecular mechanisms, preventive strategies, and early monitoring [J]. Mol Pharmacol, 2019, 96(2): 219-232. Thorn C F, Oshiro C, Marsh S, et al. Doxorubicin pathways: Pharmacodynamics and adverse effects [J]. Pharmacogenet Genomics, 2011, 21(7): 440-446. Menna P, Salvatorelli E. Primary prevention strategies for anthracycline cardiotoxicity: A brief overview [J]. Chemotherapy, 2017, 62(3): 159-168. Langer S W. Dexrazoxane for the treatment of chemotherapy-related side effects [J]. Cancer Manag Res, 2014, 6: 357-363. 鲍敏, 陈群, 赵森. 中药治疗乳腺癌的药理作用机制和临床应用研究进展[J]. 中草药, 2025, 56(21): 7983-7994. 王卓溪, 班继芳, 客蕊. 补益类中药注射液联合化疗治疗非小细胞肺癌的网状Meta分析[J]. 中医药导报, 2020, 26(16): 167-175. 付雨萱, 李广荣, 杜豪颖, 等. 基于文献计量学的中药抗癌领域研究现状与趋势分析[J]. 药物评价研究, 2025, 48(6): 1628-1644. 陶智会, 仝欣, 徐蔚杰, 等. 中药序贯联合化疗治疗非小细胞肺癌的减毒增效临床观察[J]. 世界中医药, 2021, 16(3): 477-481. 郝炜, 刘胜. 中医药防治蒽环类抗肿瘤药物所致心脏毒性研究进展[J]. 上海中医药杂志, 2016, 50(6): 99-102. 廖江龙, 范子祥, 孟秋月, 等. 丹参活性成分抗肿瘤分子机制研究进展[J]. 中草药, 2024, 55(18): 6402-6415. 李梓慕, 王斯琦, 杨丽丽, 等. 人参-丹参-黄芪防治阿霉素所致心脏毒性的作用机制研究[J]. 海南医科大学学报, 2026, 32(13): 1012-1023. You J S, Pan T L, Lee Y S. Protective effects of Danshen (Salvia miltiorrhiza) on adriamycin-induced cardiac and hepatic toxicity in rats [J]. Phytother Res, 2007, 21(12): 1146-1152. 李海文, 杨志明, 高福萍, 等. 丹参多酚对阿霉素心脏毒性损伤保护机制的研究[J]. 毒理学杂志, 2019, 33(4): 293-297. Kong C Y, Guo Z, Song P, et al. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: Oxidative stress and cell death [J]. Int J Biol Sci, 2022, 18(2): 760-770. Yi Y D, Zhang H B, Chen M Y, et al. Inhibition of multiple uptake transporters in cardiomyocytes/mitochondria alleviates doxorubicin-induced cardiotoxicity [J]. Chem Biol Interact, 2023, 382: 110627. Luanpitpong S, Chanvorachote P, Nimmannit U, et al. Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination [J]. Biochem Pharmacol, 2012, 83(12): 1643-1654. Mantawy E M, El-Bakly W M, Esmat A, et al. Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis [J]. Eur J Pharmacol, 2014, 728: 107-118. Zhang E, Shang C G, Ma M T, et al. Polyguluronic acid alleviates doxorubicin-induced cardiotoxicity by suppressing Peli1-NLRP3 inflammasome-mediated pyroptosis [J]. Carbohydr Polym, 2023, 321: 121334. Zhu M M, Wang L, Yang D, et al. Wedelolactone alleviates doxorubicin-induced inflammation and oxidative stress damage of podocytes by IκK/IκB/NF-κB pathway [J]. Biomed Pharmacother, 2019, 117: 109088. Wan Y X, He B, Zhu D Y, et al. Nicotinamide mononucleotide attenuates doxorubicin-induced cardiotoxicity by reducing oxidative stress, inflammation and apoptosis in rats [J]. Arch Biochem Biophys, 2021, 712: 109050. Wu L, Wang L T, Du Y X, et al. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity [J]. Trends Pharmacol Sci, 2023, 44(1): 34-49. Ichikawa Y, Ghanefar M, Bayeva M, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation [J]. J Clin Invest, 2014, 124(2): 617-630. Wang S F, Li F Y, Qiao R R, et al. Arginine-rich manganese silicate nanobubbles as a ferroptosis-inducing agent for tumor-targeted theranostics [J]. ACS Nano, 2018, 12(12): 12380-12392. Wang B, Jin Y X, Liu J, et al. EP1 activation inhibits doxorubicin-cardiomyocyte ferroptosis via Nrf2[J]. Redox Biol, 2023, 65: 102825. Shao J R, Xiao R, Wang T, et al. BRD4770 protects against DOX-induced cardiotoxicity by inhibiting apoptosis and ferroptosis [J]. Sci Adv, 2025, 11(28): eadw1720. Abudureyimu M, Wang G Z, Qin X, et al. CD74 deficiency protects against doxorubicin cardiotoxicity through RRM2-mediated regulation of ferroptosis [J]. Acta Pharm Sin B, 2026, 16(5): 2982-3000. Chu X, Zheng H, Sun J Y, et al. Acteoside targeting glutamine synthetase ameliorates doxorubicin-induced cardiotoxicity by inhibiting ferroptosis [J]. Phytomedicine, 2026, 153: 157979. Zhang P P, Lu H, Wu Y, et al. COX5A alleviates doxorubicin-induced cardiotoxicity by suppressing oxidative stress, mitochondrial dysfunction and cardiomyocyte apoptosis [J]. Int J Mol Sci, 2023, 24(12): 10400. Zhao L Q, Zhang B L. Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes [J]. Sci Rep, 2017, 7: 44735. Christidi E, Brunham L R. Regulated cell death pathways in doxorubicin-induced cardiotoxicity [J]. Cell Death Dis, 2021, 12(4): 339. Hansen M, Rubinsztein D C, Walker D W. Autophagy as a promoter of longevity: Insights from model organisms [J]. Nat Rev Mol Cell Biol, 2018, 19(9): 579-593. Tan N N, Luo H W, Li W L, et al. The dual function of autophagy in doxorubicin-induced cardiotoxicity: Mechanism and natural products [J]. Semin Cancer Biol, 2025, 109: 83-90. Li D L, Wang Z V, Ding G Q, et al. Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification [J]. Circulation, 2016, 133(17): 1668-1687. Jia C, Chen H W, Zhang J, et al. Role of pyroptosis in cardiovascular diseases [J]. Int Immunopharmacol, 2019, 67: 311-318. Zheng X B, Zhong T, Ma Y S, et al. Bnip3 mediates doxorubicin-induced cardiomyocyte pyroptosis via Caspase-3/GSDME [J]. Life Sci, 2020, 242: 117186. Tavakoli Dargani Z, Singla D K. Embryonic stem cell-derived exosomes inhibit doxorubicin-induced TLR4-NLRP3-mediated cell death-pyroptosis [J]. Am J Physiol Heart Circ Physiol, 2019, 317(2): H460-H471. Sun Z Z, Lu W Q, Lin N, et al. Dihydromyricetin alleviates doxorubicin-induced cardiotoxicity by inhibiting NLRP3 inflammasome through activation of SIRT1[J]. Biochem Pharmacol, 2020, 175: 113888. Zeng C, Duan F Q, Hu J, et al. NLRP3 inflammasome-mediated pyroptosis contributes to the pathogenesis of non-ischemic dilated cardiomyopathy [J]. Redox Biol, 2020, 34: 101523. Huang X X, Chen Y L, Zhang Y N, et al. Pterostilbene alleviates doxorubicin-induced cardiotoxicity by inhibiting cardiomyocytes pyroptosis mediated by the IL-6/STAT3-Caspase-3/GSDME axis and M1 polarization of macrophages [J]. Pharmacol Res, 2026, 225: 108129. Ma Y, Wang Y J, Chen R Z, et al. Exosomal transfer of pro-pyroptotic miR-216a-5p exacerbates anthracycline cardiotoxicity through breast cancer-heart pathological crosstalk [J]. Signal Transduct Target Ther, 2025, 10(1): 157. 钟明志, 毛莉, 姜媛媛, 等. 基于ISSR和SCoT分子标记的丹参遗传多样性评价及生境因子对丹酚酸和丹参酮的影响[J]. 中草药, 2024, 55(12): 4171-4184. 陈嘉慧, 张雅心, 刘孟华, 等. 基于UPLC-Q-TOF-MS/MS技术的丹参水提液全成分分析[J]. 广东药科大学学报, 2020, 36(1): 1-9. 张立国, 黄凯雯, 倪力军, 等. HPLC-MS/MS法鉴定丹参与紫丹参的水溶性成分[J]. 中成药, 2022, 44(12): 4063-4067. 王昕, 施阳扬, 万梅绪, 等. 丹参有效成分及其制剂抗抑郁药理作用研究进展[J]. 药物评价研究, 2025, 48(2): 296-306. 柴争妍, 彭新, 杨琦帆, 等. 丹参及其药对药理作用及临床应用研究进展[J]. 安徽中医药大学学报, 2024, 43(6): 108-112. 杨娜, 黄玮, 单兰兰, 等. UPLC-Q-TOF/MS结合数据后处理快速分类及鉴定丹参成分[J]. 时珍国医国药, 2019, 30(10): 2408-2412. 刘崇斌, 王伊林, 柴花, 等. 丹参多酚酸盐对阿霉素诱导的扩张型心肌病大鼠心功能的影响及机制研究[J]. 临床心血管病杂志, 2016, 32(2): 134-138. 张旼旼, 黄新宇, 戴慧. 丹参多酚酸盐抑制氧化应激减轻阿霉素诱导的心脏毒性研究[J]. 中国现代医生, 2023, 61(26): 119-124. Li G H, Li Y R, Jiao P, et al. Therapeutic potential of Salviae Miltiorrhizae Radix et Rhizoma against human diseases based on activation of Nrf2-mediated antioxidant defense system: Bioactive constituents and mechanism of action [J]. Oxid Med Cell Longev, 2018, 2018(1): 7309073. Jiang Q Q, Chen X, Tian X, et al. Tanshinone I inhibits doxorubicin-induced cardiotoxicity by regulating Nrf2 signaling pathway [J]. Phytomedicine, 2022, 106: 154439. 姜茜茜, 张敬美, 薛思明, 等. 丹参酮I基于Akt-Nrf2抗氧化通路减轻多柔比星诱导的心脏毒性[J]. 药学学报, 2022, 57(10): 3077-3085. Hong H J, Liu J C, Chen P Y, et al. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway [J]. Int J Cardiol, 2012, 157(2): 174-179. 曹杰红, 徐宁红, 谭华清. 丹参酮IIA对阿霉素所致大鼠心肌损伤的保护作用[J]. 中国医药导报, 2014, 11(24): 25-28. 王朝华, 徐勤, 肖慧琼, 等. 丹参酮IIA通过AMPK介导的自噬减轻阿霉素所致H9c2心肌细胞损伤[J]. 中国病理生理杂志, 2019, 35(3): 406-410. 陈伟光, 曾艳芳, 范丽锋. 丹参酮IIA抑制自噬减轻阿霉素诱导的心肌损伤[J]. 海峡药学, 2022, 34(11): 28-32. 张文静, 谢萍, 苏鹏, 等. 丹参酮IIA磺酸钠对阿霉素致心肌损伤的保护作用[J]. 实用医学杂志, 2015, 31(19): 3143-3146. 于影, 宝云龙, 杨莉, 等. 磷酸肌酸钠及丹参酮IIA磺酸钠对阿霉素心肌病大鼠心室肌细胞单通道钙电流作用研究[J]. 中国分子心脏病学杂志, 2014, 14(6): 1149-1152. 王伊林, 单晓彤, 柴花, 等. 丹参酮IIA磺酸钠腹腔注射对阿霉素心肌病大鼠心功能及左心室纤维化的影响[J]. 山东医药, 2016, 56(7): 34-36. 宝云龙, 哈申高娃, 杨莉, 等. 磷酸肌酸钠及丹参酮IIA磺酸钠对阿霉素心肌病大鼠内质网应激介导心肌细胞凋亡作用研究[J]. 中国分子心脏病学杂志, 2014, 14(5): 1085-1088. Wang X P, Wang Q Y, Li W L, et al. TFEB-NF-κB inflammatory signaling axis: A novel therapeutic pathway of dihydrotanshinone I in doxorubicin-induced cardiotoxicity [J]. J Exp Clin Cancer Res, 2020, 39(1): 93. Zhang Y S, Chen L, Li F, et al. Cryptotanshinone protects against adriamycin-induced mitochondrial dysfunction in cardiomyocytes [J]. Pharm Biol, 2016, 54(2): 237-242. Chen R C, Sun G B, Yang L P, et al. Salvianolic acid B protects against doxorubicin induced cardiac dysfunction via inhibition of ER stress mediated cardiomyocyte apoptosis [J]. Toxicol Res, 2016, 5(5): 1335-1345. Yu J, Gao H W, Wu C H, et al. Diethyl blechnic, a novel natural product isolated from Salvia miltiorrhiza Bunge, inhibits doxorubicin-induced apoptosis by inhibiting ROS and activating JNK1/2[J]. Int J Mol Sci, 2018, 19(6): 1809. 张梦瑶, 张咪, 韩彦弢, 等. 丹参葛根提取物对阿霉素引发小鼠心力衰竭的作用[J]. 青岛大学学报: 医学版, 2023, 59(6): 894-897. 何琦, 史华, 丹阳, 等. 加味丹参饮对慢性心力衰竭大鼠心脏功能和血清炎性因子IL-6及TNF-α的影响[J]. 吉林大学学报: 医学版, 2019, 45(1): 63-68. 邹亚兴, 吴文宇, 罗莉, 等. 苓桂术甘汤对多柔比星所致心力衰竭大鼠的改善作用及其机制[J]. 中国中医基础医学杂志, 2018, 24(7): 912-915. 潘熠, 林谦, 魏兰, 等. 益气泻肺汤加减方对阿霉素所致心脏毒性干预作用的机制研究[J]. 中西医结合心脑血管病杂志, 2024, 22(21): 3850-3858. 辛艳飞, 周国亮, 韩滨, 等. 5种中药注射剂对多柔比星所致心肌H9c2损伤保护作用[J]. 中华中医药学刊, 2012, 30(3): 483-485. Feng K, Liu Y X, Sun J, et al. Compound Danshen Dripping Pill inhibits doxorubicin or isoproterenol-induced cardiotoxicity [J]. Biomed Pharmacother, 2021, 138: 111531. Zhang J M, Li W L, Xue S M, et al. Qishen Granule attenuates doxorubicin-induced cardiotoxicity by protecting mitochondrial function and reducing oxidative stress through regulation of Sirtuin 3[J]. J Ethnopharmacol, 2024, 319(Pt1): 117134. 邹国良, 仲维莉. 参芪益心方对心力衰竭大鼠心肌纤维化及其血清NT-proBNP水平的影响[J]. 世界临床药物, 2019, 40(4): 266-270. 王睿, 徐长庆, 王伟. 丹参注射液对阿霉素所致心肌细胞损伤的保护作用[J]. 齐齐哈尔医学院学报, 2007, 28(1): 16-18. 王博宇, 王嘉萌, 李松哲, 等. 通消阳和颗粒在多柔比星治疗4T1乳腺癌小鼠中的增效减毒作用及其机制研究[J]. 中药药理与临床, 2026, 42(2): 17-24. 李增才, 刘现忠, 王兵济. 丹参酮IIA磺酸钠注射液联合阿霉素对化疗致心肌损伤的疗效观察[J]. 实用临床医药杂志, 2016, 20(7): 170-171. 黄智芬, 韦劲松, 杨泽江, 等. 注射用丹参在恶性肿瘤患者化疗中的应用[J]. 中医学报, 2013, 28(5): 622-623. 王莉, 王玉娟, 刘东利. 丹参川芎嗪注射液对Ⅲ期非小细胞肺癌患者放化疗所致心肌损害的保护作用及血流动力学参数影响[J]. 北京中医药, 2020, 39(10): 1070-1074. 王晓聪, 宫爱民. 复方丹参滴丸治疗乳腺癌CAF方案化疗致心脏毒性疗效观察[J]. 河南肿瘤学杂志, 2004, 17(4): 290-291. 王灿, 江华, 徐其锋, 等. 复方丹参滴丸对乳腺癌术后化疗患者抗氧化能力及心脏保护作用分析[J]. 中华中医药学刊, 2020, 38(11): 56-58.
PDF下载
全屏
36
6
关闭全屏
北京市海淀区学院南路86号
010-62662699（运营及技术支持）
qkjq@cast.org.cn
